Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.31 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15883182 | 0.89 | ALDH1A1 (0.39) | ALDH1A1CYP1A1CYP1B1P2RX3P2RX2 | |
| SCHEMBL15874004 | 0.89 | ALDH1A1 (0.39) | ALDH1A1CYP1A1CYP1B1P2RX3P2RX2 | |
| SCHEMBL17341690 | 0.83 | ALDH1A1 (0.33) | ALDH1A1CYP1A1CYP1B1P2RX3P2RX2 | |
| SCHEMBL22708260 | 0.69 | TYR (0.38) | ALDH1A1CYP2D6 | |
| SCHEMBL3433939 | 0.66 | ALDH1A1 (0.48) | ALDH1A1CYP1A1CYP1B1CYP2D6 | |
| SCHEMBL2735020 | 0.65 | ALDH1A1 (0.46) | ALDH1A1CYP1A1CYP1B1P2RX3P2RX2 | |
| SCHEMBL28450440 | 0.65 | ALDH1A1 (0.46) | ALDH1A1CYP1A1CYP1B1P2RX3P2RX2 | |
| SCHEMBL5080340 | 0.65 | CA1 (0.58) | ALDH1A1 | |
| SCHEMBL7026756 | 0.64 | ERN1 (0.47) | ALDH1A1CYP1A1CYP1B1HTT | |
| SCHEMBL23735887 | 0.63 | CYP2D6 (0.35) | ALDH1A1HTTCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572348-B2 | Syntheses of N-heterocyclic carbenes and intermediates therefor | UMICORE AG & CO. KG (DE) | 2023-02-07 | — | — | US | disclosed |
| US-20210317088-A9 | SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR | UMICORE AG & CO. KG (DE) | 2021-10-14 | — | — | US | disclosed |
| US-20200354323-A1 | SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR | UMICORE AG & CO. KG (DE) | 2020-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572348-B2 | Syntheses of N-heterocyclic carbenes and intermediates therefor | GRHPR, DDC, NDC1 | ALDH1A1 726/4885CYP1A1 969/4885CYP1B1 836/4885 |
| US-20210317088-A9 | SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR | GRHPR, DDC, NDC1 | ALDH1A1 726/4885CYP1A1 969/4885CYP1B1 836/4885 |
| US-20200354323-A1 | SYNTHESES OF N-HETEROCYCLIC CARBENES AND INTERMEDIATES THEREFOR | GRHPR, DDC, NDC1 | ALDH1A1 726/4885CYP1A1 969/4885CYP1B1 836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.